Ticker

Athersys (NASDAQ: ATHX - Get Free Report) and Turn Therapeutics (NASDAQ: TTRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Institutional and Insider Ownership 19.4% of Athersys shares

Earnings and Valuation This table compares Athersys and Merck KGaA"s gross revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146,000.00 0.00 -$72.53 million ($2.03) N/A Merck KGaA $22.72 billion 0.72 $3.06 billion $6.81 18.52 Merck KGaA has higher revenue and earnings than Athersys. Athersys is

Risk and Volatility Galera Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500. Valuation and Earnings This table compares Galera Therapeutics and Athersys"s gross revenue,